Schneider-Gold, Christiane

[["dc.bibliographiccitation.firstpage","1236"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.lastpage","1237"],["dc.bibliographiccitation.volume","253"],["dc.contributor.author","Schneider-Gold, Christiane"],["dc.contributor.author","Wessig, Carsten"],["dc.contributor.author","Hoepker, Martin"],["dc.contributor.author","Erdlenbruch, Bernhard"],["dc.contributor.author","Gold, Ralf"],["dc.contributor.author","Toyka, Klaus V."],["dc.date.accessioned","2018-11-07T09:21:23Z"],["dc.date.available","2018-11-07T09:21:23Z"],["dc.date.issued","2006"],["dc.identifier.doi","10.1007/s00415-006-0150-y"],["dc.identifier.isi","000241113100021"],["dc.identifier.pmid","16598612"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29091"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Dr Dietrich Steinkopff Verlag"],["dc.relation.issn","0340-5354"],["dc.title","Pregnancy and delivery of a healthy baby in autoimmune Lambert-Eaton myasthenic syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","477"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Aktuelle Neurologie"],["dc.bibliographiccitation.lastpage","480"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Schneider-Gold, C."],["dc.contributor.author","Bähr, M."],["dc.contributor.author","Gold, R."],["dc.date.accessioned","2017-09-07T11:54:11Z"],["dc.date.available","2017-09-07T11:54:11Z"],["dc.date.issued","2005"],["dc.description.abstract","Mycophenolate mofetil (MMF) is a novel immunosuppressive drug and has been applied in myasthenia gravis, dysimmune polyneuropathies, myositis, multiple sclerosis and cerebral vasculitis. The spectrum of neurological diseases in which MMF may be effective is not finally delineated. So far, only in myasthenia gravis the efficacy and safety of MMF has been evaluated by retrospective analyses, one open-label study and one placebo-controlled double blind study. in myasthenia gravis, replacement of azathioprine or cyclosporine A by MMF seems to be useful in non-responders or in case of intolerance. Further controlled studies are necessary to evaluate short-term and long-term effects of MMF in neurological autoimmune diseases."],["dc.description.abstract","Mykophenolatmofetil (MMF) erweitert das Spektrum immunmodulatorischer Substanzen, die in der Therapie neuroimmunologischer Erkrankungen eingesetzt werden können. Bisher sind positive therapeutische Effekte bei Myasthenia gravis, Myositiden, autoimmunen Polyneuropathien, multipler Sklerose und zerebraler Vaskulitis beschrieben worden. Das Spektrum möglicher Indikationen für die Verabreichung von MMF auf neurologischem Fachgebiet ist aktuell noch nicht abschließend definiert. Die Indikation für den „Off-label”-Einsatz von MMF muss im Einzelfall sorgfältig geprüft werden. Bei Myasthenia gravis konnten sowohl retrospektive Analysen als auch eine offene Studie und eine randomisierte plazebokontrollierte Studie die Wirksamkeit und gute Verträglichkeit belegen. MMF scheint daher eine mögliche therapeutische Alternative zu Azathioprin oder Ciclosporin A bei Unverträglichkeiten oder unzureichender Wirksamkeit zu sein. Weitere kontrollierte Studien sind notwendig, um die Kurz- und Langzeiteffekte von MMF bei neuroimmunologischen Erkrankungen genauer zu evaluieren."],["dc.identifier.doi","10.1055/s-2005-866941"],["dc.identifier.gro","3143799"],["dc.identifier.isi","000232782200005"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1353"],["dc.language.iso","de"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","0302-4350"],["dc.title","Mycophenolate mofetil: A new therapeutic option in neuroimmunological diseases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","284"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Muscle & Nerve"],["dc.bibliographiccitation.lastpage","291"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Schneider-Gold, Christiane"],["dc.contributor.author","Hartung, Hans-Peter"],["dc.contributor.author","Gold, Ralf"],["dc.date.accessioned","2018-11-07T09:23:04Z"],["dc.date.available","2018-11-07T09:23:04Z"],["dc.date.issued","2006"],["dc.description.abstract","Mycophenolate mofetil (MMF) and tacrolimus are novel immunosuppressive drugs, both first established in transplantation medicine and now used increasingly in neuroimmunological diseases including myasthenia gravis, dysimmune polyneuropathies, and myositis. In myasthenia gravis, the efficacy and safety of MMF has been shown by one open-label trial; one small, double-blind, placebo-controlled trial; and a few retrospective analyses. Similarly, for tacrolimus the greatest experience and evidence for efficacy and safety have been gathered in myasthenia gravis. MMIF and tacrolimus have both been used as an alternative treatment for various other autoimmune diseases in which azathioprine or cyclosporine were not sufficiently effective. However, experience with tacrolimus in dysimmune polyneuropathies and myositis is limited. At this time, the available data suggest that MMF and tacrolimus are well suited for long-term immunosuppression in patients with myasthenia gravis. The spectrum of neuroimmunological diseases in which these drugs may be used has not been finally delineated and will require further controlled studies."],["dc.identifier.doi","10.1002/mus.20543"],["dc.identifier.isi","000239846800003"],["dc.identifier.pmid","16583368"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29492"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","John Wiley & Sons Inc"],["dc.relation.issn","0148-639X"],["dc.title","Mycophenolate mofetil and tacrolimus: New therapeutic options in neuroimmunological diseases"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","406"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Muscle & Nerve"],["dc.bibliographiccitation.lastpage","409"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Lee, De-Hyung"],["dc.contributor.author","Linker, Ralf A."],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Schneider-Gold, Christiane"],["dc.contributor.author","Chan, Andrew"],["dc.contributor.author","Gold, Ralf"],["dc.date.accessioned","2018-11-07T11:17:54Z"],["dc.date.available","2018-11-07T11:17:54Z"],["dc.date.issued","2008"],["dc.description.abstract","Intravenous application of immunoglobulins (IVIg) is an effective and usually well tolerated yet costly therapeutic regimen in chronic inflammatory demyelinating polyneuropathy (CIDP). We report two CIDP patients treated with subcutaneous infusion of immunoglobulins (SCIg) after IVIg therapy was shown to be effective. Application of SCIg was well tolerated, easy to manage, and led to stabilization of the disease course. SCIg may represent an effective new therapeutic option in CIDP and is associated with a cost reduction of at least 50% compared to IVIg therapy."],["dc.identifier.doi","10.1002/mus.20909"],["dc.identifier.isi","000253403900017"],["dc.identifier.pmid","17918749"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54921"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","John Wiley & Sons Inc"],["dc.relation.issn","0148-639X"],["dc.title","Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]